Loading...
XNAS
MBOT
Market cap48mUSD
Oct 08, Last price  
1.07USD
1D
-4.46%
1Q
-43.39%
Jan 2017
-98.83%
Name

Microbot Medical Inc

Chart & performance

D1W1MN
XNAS:MBOT chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
45.11%
Rev. gr., 5y
%
Revenues
0
92,85056,722231,730992,8701,427,0001,221,0001,368,0001,203,0001,012,000117,0000000000000
Net income
-13m
L+14.85%
-18,948,000-25,023,000-29,087,000-27,026,000-25,244,000-21,329,000-28,491,000-26,439,159-32,741,000-36,415,000-9,663,000-7,589,000-7,260,000-7,247,000-9,169,000-11,313,000-13,168,000-10,740,000-11,443,000-13,142,000
CFO
-13m
L+47.80%
-16,104,120-20,856,746-22,740,421-24,682,669-24,519,913-22,058,283-19,869,344-23,322,000-27,352,431-765,000-786,000-4,856,000-5,310,000-6,451,000-7,252,000-9,354,000-11,549,000-8,533,000-8,827,000-13,046,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.

Key people

Harel Gadot
Chairman of the Board, President, Chief Executive Officer · since 2016
Rachel Vaknin
Chief Financial Officer · since 2022
Simon Sharon
Chief Technology Officer, General Manager of Microbot Israel · since 2021
Juan Diaz-Cartelle
Chief Medical Officer · since 2023
Scott Burell
Independent Director · since 2016
Prattipati Laxminarain
Independent Director · since 2017
Martin Madden
Independent Director · since 2017
Aileen Stockburger
Independent Director · since 2020
Tal Wenderow
Independent Director · since 2020
David Wilson
Independent Director · since 2024
URL
http://www.microbotmedical.com
IPO date
Mar 25, 1992
Employees
18
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
25 Recreation Park Drive
Unit 108
Hingham, MA 02043
US
Previous name
StemCells, Inc.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT